Introduction dual specificity. This approach yields a homogeneous bispecific Bispecific antibodies (BsAb) have significant potential for IgG-like antibody product with each molecule containing four human applications and have shown promise in several smallantigen binding sites, two for each of its target antigens (Figure scale clinical trials as cancer imaging and therapy agents 1). The BsAb retains not only antigen binding efficiency but (Fanger et al., 1993; Curnow, 1997; De Gast et al., 1997) .
also the biological activity of its component antibodies. Broad clinical evaluation of BsAb has been hampered, however, by the lack of efficient production methods. In recent years, a
Materials and methods variety of recombinant methods have been developed for
Proteins and antibodies the production of bispecific and/or bivalent and multivalent antibody fragments (for reviews, see Holliger and Winter, Vascular endothelial growth factor (VEGF), kinase insert domain-containing receptor-alkaline phosphatase fusion pro-1993; Plückthun and Pack, 1997) . Bispecificity and/or bivalency have been accomplished by fusing two tein (KDR-AP) and its mouse homolog, fetal liver kinase 1 (Flk-1)-AP, were expressed in baculovirus and NIH 3T3 cells, single-chain Fv (scFv) or Fab via flexible linkers (Mallender and Voss,1994; Mack et al., 1995; Zapata et al., 1995) , leucine respectively, and purified following the procedures described . KDR extracellular domain (ECD) immunozipper (De Kruif and Logtenberg, 1996) , C H C L -heterodimerization (Müller et al., 1998a) and diabody format (Holliger et al., globulin (Ig) domain deletion mutants were constructed by PCR cloning, expressed in NIH 3T3 cells and purified as 1993; . On the other hand, multivalency is achieved by the addition of multimerization sequences at the described (Lu et al., 2000) . The definition of KDR ECD Ig receptor (from amino acid Met1 to Val742); KDR(Ig1-3), the mutant containing the three N-terminal ECD Ig domains (from of 19 amino acids, MGWSCIILFLVATATGVHS, was used for amino acid Met1 to Lys327); and KDR(Ig3-7), the mutant the secretion of both the light and the heavy chains. containing KDR ECD Ig domains 3-7 (from amino acid JZZ-2: 5Ј CTA GTA GCA ACT GCC ACC GGC GTA CAT TCA CAG GTC AAG CTG C 3Ј Asp225 to Val742). The isolation of the anti-KDR single-chain JZZ-3: 5Ј TCG AAG GAT CCA CTC ACC TTT TAT TTC CAG C 3Ј Fv (scFv) p1C11 and scFv p4G7 from a phage display library BamHI constructed from a mouse immunized with KDR has been p1C11VL3-2: 5Ј TCG ATC TAG AAG GAT CCA CTC ACG TTT TAT TTC CAG 3Ј reported previously Lu et al., 1999) . Diabody BamHI DAB p4G7, a form of bivalent scFv fragment (Holliger et al., : 5Ј GGT CAA AAG CTT ATG GGA TGG TCA TGT ATC ATC CTT TTT CTA 1993; was constructed from scFv p4G7 as GTA GCA ACT 3Ј HindIII described previously Lu et al., 1999) .
JZZ-18: 5Ј TCT CGG CCG GCT TAA GCT GCG CAT GTG TGA GT 3Ј
C-p1C11, a mouse-human chimeric IgG1 antibody constructed NaeI from scFv p1C11 and C225, a chimeric IgG1 antibody directed Separate expression vectors for the light and heavy chains against epidermal growth factor (EGF) receptor, were both of Bs(scFv) 4 -IgG were constructed ( Figure 2A ). The cloned produced at ImClone Systems (New York) (Zhu et al., 1999) . scFv p4G7 gene was digested with HindIII and BamHI and Construction of expression vectors for BsAb-IgG [Bs(scFv) 4 ligated into the vector pKN100 (a gift from Dr T.Jones, MRC IgG] and BsAb-Fab[Bs(svFv) Collaborative Centre, London, UK) containing the human κ light-chain constant region (C L ) to create the expression vector The gene encoding scFv p4G7 was amplified from the scFv expression vector by PCR using primers, JZZ-2 and JZZ-3.
for the BsAb-IgG light chain, BsIgG-L. The cloned scFv p1C11 gene was digested with HindIII and BamHI and ligated The leader peptide sequence for protein secretion in mammalian cells was then added to the 5Ј of the scFv encoding sequence into the vector pG1D105 (a gift from Dr T.Jones) containing the human IgG1 (γ) heavy-chain constant domain (C H ) to by PCR using primers JZZ-12 and JZZ-3. Similarly, the gene encoding scFv p1C11 was amplified from the scFv expression create the expression vector for the BsAb-IgG heavy chain, BsIgG-H. vector by PCR using primers JZZ-2 and p1C11VL3-2, followed by PCR with primers JZZ-12 and p1C11VL3-2 to add the To prepare the expression vector for Bs(scFv) 2 -Fab, a stop codon was introduced into vector BsIgG-H immediately after leader peptide sequence. The same leader peptide consisting the first constant domain (C H1 ) to terminate the protein transla-HRP conjugate for scFv p4G7. The plates were washed and developed as described above. tion, by PCR using primers JZZ-12 and JZZ-18. The gene fragment was digested with HindIII and NaeI and cloned into FACS analysis vector pG1D105 to create vector BsFab-H. All constructs were Early-passage HUVEC cells were grown in growth factorexamined by restriction enzyme digestion and verified by depleted EBM-2 medium overnight to induce the expression dideoxynucleotide sequencing.
of KDR receptor. The cells were harvested and washed three times with PBS, incubated with 5 µg/ml Bs(scFv) 4 -IgG or Antibody expression and purification c-p1C11 for 1 h at 4°C, followed by incubation with a COS cells were co-transfected with equal amounts of DNA FITC-labeled rabbit anti-human Fc antibody (Cappel, Organon from vector BsIgG-L and BsIgG-H or BsIgG-L and BsFab-H, Teknika) for an additional 1 h. The cells were washed and for transient expression of Bs(scFv) 4 -IgG and Bs(scFv) 2 -Fab, analyzed with a flow cytometer (Zhu et al., 1999) . respectively, following the procedure described previously Binding kinetic analysis (Zhu et al., 1999) . The cells were switched to serum-free medium 24 h after the transfection. The conditioned supernatant
The binding kinetics of the BsAb to both KDR and Flk-1 were was collected at 48 and 120 h after the transfection. The measured by surface plasmon resonance, using a BIAcore Bs(scFv) 4 -IgG and Bs(scFv) 2 -Fab were purified from the biosensor (Pharmacia Biosensor). KDR-AP or Flk-1-AP fusion pooled supernatant by affinity chromatography using a Protein proteins were immobilized onto a sensor chip and various G column following the protocol described by the manufacturer antibodies were injected at concentrations ranging from 25 to (Pharmacia Biotech, Piscataway, NJ). The antibody-containing 200 nM. Sensorgrams were obtained at each concentration and fractions were pooled, buffer exchanged into PBS and concenwere evaluated using a program, BIA Evaluation 2.0, to trated using Centricon 10 concentrators (Amicon, Beverly, determine the rate constants k on and k off . K d was calculated as MA). The purity of the antibodies was analyzed by SDSthe ratio of rate constants k off /k on . PAGE. The concentration of purified antibody was determined VEGF blocking and phosphorylation inhibition assay by ELISA using goat anti-human IgG Fc specific antibody as
In the blocking assay, various amounts of BsAb or c-p1C11 the capture agent and HRP-conjugated goat anti-human Φ were mixed with a fixed amount of KDR-AP or Flk-1-AP and chain antibody as the detection agent. A standard curve was incubated at room temperature for 1 h. The mixtures were then calibrated using clinical grade antibodies, C225 or c-p1C11.
transferred to VEGF 165 -coated 96-well plates and incubated at room temperature for an additional 2 h, after which the plates
Bispecific binding of the BsAb to KDR
were washed five times. The VEGF-bound AP activity was Two different assays were carried out to demonstrate the dual quantified as described (Zhu, et al., , 1999 . specificity of the BsAb. In the direct binding assay, a 96-KDR phosphorylation assay was carried out following the well plate (Nunc, Roskilde, Denmark) was first coated with procedure described previously (Zhu et al., , 1999 , using KDR(Ig1-7)-AP, KDR(Ig1-3)-AP or KDR(Ig3-7)-AP fusion a stable 293 cell line transfected with the full length KDR proteins (1.0 µg/mlϫ100 µl per well) using a rabbit anti-AP (ImClone Systems). Briefly, the transfected 293 cells (~3ϫ10 6 antibody (DAKO-immunogloblins, Denmark) as the capturing cells per plate) were incubated in the presence or absence of agent. The plate was then incubated with the BsAb, c-p1C11
antibodies for 15 min, followed by stimulation with 20 ng/ml or DAB p4G7 at room temperature for 1 h, followed by of VEGF165 at RT for an additional 15 min. The cells incubation with rabbit anti-human IgG Fc specific antibodywere then lysed and the cell lysate was used for KDR HRP conjugate (Cappel, Organon Teknika, West Chester, PA) phosphorylation assays. The KDR receptor was immunoprefor the BsAb and c-p1C11 or mouse anti-E tag antibody-HRP cipitated from the cell lysates with Protein A Sepharose beads conjugate (Pharmacia Biotech) for DAB p4G7. The plates (Santa Cruz Biotechnology, CA) coupled to an anti-KDR were washed five times, TMB peroxidase substrate (KPL, antibody, Mab 4.13 (ImClone Systems). Proteins were resolved Gaithersburg, MD) was added and the OD at 450 nm read with SDS-PAGE and subjected to Western blot analysis. To using a microplate reader (Molecular Device, Sunnyvale, CA) detect KDR phosphorylation, blots were probed with an anti- . In the cross-linking assay, the antibodies phosphotyrosine Mab, PY20 (ICN Biomedicals, Aurora, OH). were first incubated in solution with KDR(Ig1-7)-AP, The signals were detected using enhanced chemiluminescence KDR(Ig1-3)-AP or KDR(Ig3-7)-AP. The mixtures were trans-(Amersham, Arlington Heights, IL). The blots were reprobed ferred to a 96-well plate coated with KDR(Ig1-3) (untagged) with a polyclonal anti-KDR antibody (ImClone Systems) to and incubated at room temperature for 2 h. The plate was ensure that an equal amount of protein was loaded in each washed and the KDR(Ig1-3) (untagged)-bound AP activity lane of the SDS-polyacrylamide gels. was measured by the addition of AP substrate, p-nitrophenyl phosphate (Sigma), and the OD was read at 405 nm (Zhu Results et al., 1998) .
Construction of Bs(scFv) 4 -IgG and Bs(scFv) 2 -Fab Quantitative binding of Bs(scFv) 4 -IgG and Bs(scFv) 2 -Fab to
Two anti-KDR scFv antibodies, scFv p1C11 and p4G7, were KDR and Flk-1 used for the construction of Bs(scFv) 4 -IgG and Bs(scFv) 2 -Fab Various amounts of Bs(scFv) 4 -IgG, Bs(scFv) 2 -Fab, c-p1C11
( Figure 2A ). ScFv p1C11 binds specifically to KDR and or scFv p4G7 were added to 96-well Maxi-sorp microtiter blocks KDR/VEGF interaction, whereas scFv p4G7 binds to plates (Nunc) coated with either KDR-AP or Flk-1-AP (100 ng both KDR and its mouse homolog, Flk-1, but does not block protein per well) and incubated at room temperature for 1 h, either KDR/VEGF or Flk-1/VEGF interaction (Zhu et al., followed by incubation at room temperature for 1 h with 1998; Lu et al., 1999) . Epitope mapping studies revealed that rabbit anti-human IgG Fc specific antibody-HRP conjugate for p1C11 binds to epitope(s) located within KDR ECD Ig domain 1-3, whereas the epitope(s) for p4G7 are located within Ig bispecific antibodies and c-p1C11 or mouse anti-E tag antibody-domains 6 and 7 (Lu et al., 2000) . Gene segments encoding scFv p1C11 and p4G7 were fused to the N-terminus of C H1 and C L of a human IgG1 molecule, respectively, to create expression vectors BsIgG-H and BsIgG-L (Figure 2A ). This arrangement replaces the original V H and V L domains of an IgG with two scFv molecules, each constituting an independent antigen-binding unit (Figure 1 ). Co-expression of BsIgG-H and BsIgG-L yields an IgG-like tetravalent molecule, Bs(scFv) 4 -IgG, with dual specificity (Figure 1) . A bispecific, bivalent Fab-like molecule (Figure 1) , Bs(scFv) 2 -Fab, was also produced by co-expression of BsIgG-L and BsFab-H. Vector BsFab-H was constructed from BsIgG-H by introducing a stop codon at the end of C H1 domain (Figure 2A ).
Expression and purification of Bs(scFv) 4 -IgG and Bs(scFv) 2 -Fab
The Bs(scFv) 4 -IgG and Bs(scFv) 2 -Fab were transiently expressed in COS cells and purified from the cell culture supernatant by an affinity chromatography using a Protein G column. The purified BsAb were analyzed by SDS-PAGE ( Figure 2B ). Under non-reducing condition, Bs(scFv) 4 -IgG gave rise to a single band with a molecular mass of~200 kDa, whereas Bs(scFv) 2 -Fab gave a major band of~75 kDa ( Figure  2B , lanes 2 and 3). Under reducing conditions, Bs(scFv) 4 -IgG yielded two major bands with the expected mobility for scFv-C H1 -C H2 -C H3 fusion (~63 kDa) and scFv-C L fusion (~37 kDa), respectively ( Figure 2B , lane 5). On the other hand, Bs(scFv) 2 -Fab gave rise to two major bands with molecular mass of 38 kDa and 37 kDa, representing the scFv-C H1 and scFv-C L fusions, respectively ( Figure 2B , lane 6). As a control, cp1C11, a chimeric IgG1 antibody, gave rise to one band of 150 kDa under non-reducing conditions ( Figure 2B , lane 1) and two bands of~50 kDa (the heavy chain, V H -C H1 -C H2 -C H3 fusion) and~25 kDa (the light chain, V L -C L fusion) under reducing conditions ( Figure 2B , lane 5). Dual specificity of the BsAb Dual specificity of the BsAb was assayed using the full-length KDR ECD and two of its Ig domain-deletion mutants ( Figure   Fig. 3 . ELISA assays for the bispecificity of Bs(scFv) 4 -IgG and Bs(scFv) 2 -3A). As seen previously, p1C11 only binds to KDR mutants using several KDR ECD Ig domain-deletion mutants that are either untagged or tagged with AP. In this assay, the BsAb were first incubated with KDR(Ig1-7)-AP, KDR(Ig1-3)-AP or Antigen binding by BsAb KDR (Ig3-7) -AP. The mixtures were transferred to a microtiter plate coated with KDR(Ig1-3) (untagged), followed by measur-
The antigen binding efficiency of the BsAb was determined on immobilized KDR ( Figure 4A ) and Flk-1 ( Figure 4B ). ing KDR(Ig1-3) (untagged)-bound AP activity ( Figure 3B ). Both Bs(scFv) 4 -IgG and Bs(scFv) 2 -Fab bind effectively to all Figure 4A shows the dose-dependent binding of Bs(scFv) 4 -IgG and Bs(scFv) 2 -Fab to KDR. Both Bs(scFv) 4 -IgG and three KDR-AP variants in solution and form cross-linking complexes with the immobilized KDR(Ig1-3) (untagged), as Bs(scFv) 2 -Fab bind KDR as efficiently as one of the parent antibodies, c-p1C11. In addition, Bs(scFv) 4 -IgG and Bs(scFv) 2 -demonstrated by plate-bound AP activity ( Figure 3B ). In contrast, c-p1C11 only cross-links KDR(Ig1-3) (untagged)
Fab, but not c-p1C11, also bind to Flk-1 in a dose-dependent manner similar to scFv p4G7 ( Figure 4B ). As expected, C225, with KDR variants containing Ig domains 1-3, i.e. KDR(Ig1-7)-AP and KDR(Ig1-3)-AP, but not KDR(Ig3-7)-AP. As a chimeric antibody directed against human EGFR, did not bind to either of the antigens. expected, p4G7 fails to cross-link any KDR variants to the immobilized KDR(Ig1-3) (untagged), since p4G7 does not
Binding of the BsAb to cell surface-expressed receptor was assayed by FACS analysis. As previously seen with c-p1C11 bind KDR(Ig1-3) mutant. Phosphorylation of KDR was analyzed followed the protocol described previously (Zhu et al., , 1999 . (Zhu et al., 1999) , Bs(scFv) 4 -IgG binds efficiently to KDR Bs(scFv) 4 -IgG and c-p1C11 are 4 and 1 nM, respectively. As expressed on early passage HUVEC (data not shown).
seen with scFv p4G7, Bs(scFv) 4 -IgG did not block Flk-1 The binding kinetics of the BsAb to KDR and Flk-1 were binding to VEGF (not shown). C225, an anti-EGFR antibody, determined by surface plasmon resonance using a BIAcore showed no effect on KDR binding to VEGF. instrument (Table I ). The overall affinities (K d ) or avidity of Bs(scFv) 4 -IgG and Bs(scFv) 2 -Fab to KDR were 1.4 and 1.1 nM, KDR phosphorylation inhibition by the BsAb respectively, which are similar to those of the monovalent The biological effect of Bs(scFv) 4 -IgG on VEGF-induced scFv p1C11 and p4G7, but are 4-10-fold weaker than those receptor phosphorylation was determined using KDR-transof the bivalent c-p1C11 or DAB p4G7. On the other hand, fected 293 cells. As shown in Figure 6 , VEGF treatment Bs(scFv) 4 -IgG, which is bivalent to Flk-1, showed an avidity induces strong phosphorylation of KDR receptor. Pretreatment (K d 0.33 nM) that is similar to that of the bivalent DAB p4G7
with Bs(scFv) 4 -IgG inhibits VEGF-induced receptor phos-(K d 0.18 nM). Bs(scFv) 2 -Fab and scFv p4G7, both monovalent phorylation in a dose-dependent manner ( Figure 6 ). Further, to Flk-1, bind to Flk-1 with similar affinity (K d 1.7 and 4.2 nM, Bs(scFv) 4 -IgG is equally potent as c-p1C11 at each antibody respectively), which are 5-20-fold weaker than those of their concentration assayed. bivalent counterparts. Discussion VEGF blocking by Bs(scFv) 4 -IgG Figure 5 shows that Bs(scFv) 4 -IgG effectively block KDR-AP We have developed an efficient method for the production of IgG-like bispecific antibodies using the natural dimerization from binding to immobilized VEGF. The IC 50 , the antibody concentrations required to block 50% of KDR binding, of mechanism between IgG heavy and light chains. The original (Vaughan et al., 1996; Merchant et al., 1998) . Coexpression of one common set of light chains along with two 1). Bs(scFv) 4 -IgG is functionally expressed and assembled in mammalian cells and is capable of binding to two different sets of 'knobs-into-holes'-modified heavy chains resulted in the production of~95% functional BsAb-IgG (Merchant et al. , epitopes simultaneously, as demonstrated by the cross-linking assay ( Figure 3B ). We believe this approach is applicable to 1998). In our approach, the V H and V L domains of IgG are replaced by scFv antibodies of different specificity to form scFv antibodies recognizing virtually any pair of antigens. It is also possible to produce a similar molecule that is tetravalent (scFv) 1 -C H1 -C H2 -C H3 and (scFv) 2 -C L fusion polypeptides, respectively. Co-expression of the two fusion polypeptides in to the same epitope.
The small-size BsAb fragments may be preferable to the mammalian cells results in the formation of an IgG-like hybrid molecule, each comprising of two copies of (scFv) 1 -C H1 -C H2 -full-size BsAb-IgG for some clinical applications, for example, to promote rapid clearance for improved tumor imaging C H3 and two copies of (scFv) 2 -C L fusion polypeptides ( Figure  1) . The hybrid molecule, Bs(scFv) 4 -IgG, is bispecific and and to facilitate efficient tumor penetration. In many other applications, however, BsAb-IgG may offer additional advanttetravalent since each of its two Fab-like arms possesses two different antigen binding sites. Both scFv displayed on each ages as this format provides an IgG Fc region that can confer long serum half-life and support secondary immune functions, Fab-like arm are properly folded and immunoreactive, as demonstrated by fact that Bs(scFv) 2 -Fab is bifunctional and for example, antibody-dependent cellular cytotoxicity (ADCC) and complement mediated cytotoxicity (CMC). The major capable of cross-linking the two target antigens ( Figure 3B ). It is not clear, however, whether all the four antigen-binding hurdles in traditional methods of BsAb production include heterogeneity of the products, low yield and difficulty with sites within a Bs(scFv) 4 -IgG molecule are accessible to the target epitopes at the same time. the purification process. For example, co-expression of two sets of IgG heavy and light chains in a hybrid hybridoma may Our BsAb format, Bs(scFv) 4 -IgG, combines the features of bispecificity and bivalency. High affinities are desirable and produce up to 10 pairings (Suresh et al., 1986) . These unwanted pairings often greatly compromise the yield of BsAb and may be necessary for each arm of a BsAb destined for human therapy. For example, a bispecific anti-p185 HER2 /anti-CD3 impose significant problems with purification. Recently, two recombinant methods were developed to improve the produc-F(abЈ) 2 constructed with a higher affinity variant of an humanized anti-CD3 antibody was much more potent in mediating tion of IgG-like bispecific and/or multivalent molecules (Coloma and Morrison, 1997; Merchant et al., 1998 ; for tumor cell-killing than one constructed with an anti-CD3 variant of lower affinity (Zhu et al., 1995) . Because of the comments and review, see Hoogenboom, 1997; Dall'Acqua and Carter, 1998) . Coloma and Morrison fused an scFv avidity factor of bivalent binding, our format may be of great advantageous over the monovalent BsAb. This is particularly fragment to the C-terminus of the heavy chain of the second antibody to create an antibody heavy-chain-scFv fusion. Corelevant when constructing BsAb from antibodies of low affinity; such antibodies may require laborious and timeexpression of the antibody light chain along with the modified heavy-chain-scFv fusion results in the production of a homoconsuming affinity maturation processes to achieve a 'minimal' functional affinity. For example, our studies showed that geneous population of IgG-like, tetravalent bispecific molecule that binds to antigen A at one end and to antigen B at the Bs(scFv) 4 -IgG, which is bivalent to Flk-1, had an avidity similar to DAB p4G7, a bivalent diabody to Flk-1. The avidity other end (Coloma and Morrison, 1997) . On the other hand, strategies were developed to overcome the unwanted pairings of Bs(scFv) 4 -IgG and DAB p4G7 is~10-23-fold higher than that of their respective monovalent counterparts, the divalent between two different sets of IgG heavy and light chains coexpressed in transfected cells . The C H3 Bs(scFv) 2 -Fab and the scFv p4G7 (Table I) , demonstrating clearly the avidity enhancement from bivalent binding. domains of heavy chains were first remodeled for heterodimerization using 'knobs-into-holes' mutations in conjunction with Bs(scFv) 4 -IgG, however, possesses an approximately 8-fold slower association rate (k on ) and a 10-fold faster dissociation engineered disulfide bonds, to reduce dramatically the homodimerization between antibody heavy chains of the same rate (k off ) than DAB p4G7. This may reflect decreased accessibility of the antigen epitope to the binding sites of scFv p4G7 specificity . Light-chain mispairing was prevented by using an identical light chain for each arm of because of the presence in the close vicinity of the second (and non-functional) molecule, the KDR-specific scFv p1C11 the resulting BsAb-IgG . Antibodies of (see Figure 1) . It is of interest that the tetravalent Bs(scFv) 4 -provides an IgG Fc region that can confer a long serum halflife and support secondary immune functions, such as ADCC IgG showed the same avidity for KDR as the divalent Bs(scFv) 2 -Fab. Further, the avidity of Bs(scFv) 4 -IgG to KDR and CMC (Coloma and Morrison, 1997; Merchant et al., 1998) . is 5-7-fold lower than that of both the bivalent c-p1C11 and DAB p4G7 (Table I) . Unlike in the case of Flk-1 binding, the
